Biotechnology
BLA Accepted in China for Boan Biotech's Denosumab Injection (BA1102) for the Oncology Indications
YANTAI, China, March 21, 2023 /PRNewswire/ -- Luye Pharma Group today announced that the Biologics License Application (BLA) for BA1102 (Denosumab Injection), a biosimilar for the oncology indications developed by its subsidiary Boan Biotech, has been accepted inChina by the Center for Drug Evalu...
2023-03-21 13:46
3051
Innovent Announces Clinical Data of Multiple Trials Will be Presented at the AACR Annual Meeting 2023
ROCKVILLE, Md. and SUZHOU, China, March 21, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology ...
2023-03-21 08:00
3597
Saudi's Space Mission will be for the Benefit of Science
RIYADH, Saudi Arabia, March 21, 2023 /PRNewswire/ -- The Saudi Space Commission (SSC) have revealed the tasks and scientific research that will be conducted during the journey of the Saudi astronauts, Rayyanah Barnawi andAli Alqarni as part of the mission to the International Space Station (ISS),...
2023-03-21 00:31
2000
Sirnaomics to Present Latest Developments in Polypeptide Nanoparticle Platform at the 4th Annual RNAi-Based Therapeutics Summit
HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, March 20, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, and together with its subsidiaries, the"Group" or "Sirnaomics"), a leading biopharmaceutical company in the discovery and development of advanced RNAi thera...
2023-03-20 23:27
2536
Transcenta Holding Limited (6628.HK) to Hold 2022 Annual Results Release Conference Call
SUZHOU, China, March 20, 2023 /PRNewswire/ -- The management team of Transcenta Holding Limited (06628.HK) will attend the 2022 annual results release conference call onMarch 31, 2023. Transcenta is a clinical stage biopharmaceutical company with fully integrated capabilities in the discovery, r...
2023-03-20 21:12
2006
Hovione and Ripple Enter Strategic Partnership to Expand Epidel® Platform into Non-Ophthalmic Space
LISBON, Portugal, March 20, 2023 /PRNewswire/ -- Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a strategic partnership to expand the use of Ripple's Epidel® plat...
2023-03-20 21:00
1649
Guo Guangchang Stresses Healthy Corporate Development and Expresses Full Confidence in the Future
HONG KONG, March 20, 2023 /PRNewswire/ -- On 17 and 18 March, Guo Guangchang, Chairman of Fosun International, attended the 23rd Annual Conference of Yabuli China Entrepreneurs Forum 2023, and the 6th Shanghai Forum Themed Zhejiang Entrepreneurs in the World & the 11th Member Representative Confe...
2023-03-20 17:12
2456
ETANA HAS SECURED FINANCING FROM DEG, EAST VENTURES AND OTHER GLOBAL INVESTORS
JAKARTA, Indonesia, March 20, 2023 /PRNewswire/ -- PT Etana Biotechnologies Indonesia (Etana), an Indonesian biopharmaceutical company, has secured a new round of investment led by DEG followed by Yunfeng Capital, HighLight Capital and East Ventures. This round of financing will be used for fu...
2023-03-20 15:22
3048
Antengene Announces Five Upcoming Presentations at the 2023 American Association for Cancer Research Annual Meeting
– Five posters will showcase progress with multiple preclinical and clinical programs, including the clinical results ofATG-008 (mTORC1/2 inhibitor) and preclinical data ofATG-031 (anti-CD24 monoclonal antibody), ATG-037 (small molecule CD73 inhibitor), ATG-017 (ERK1/2 inhibitor), and ATG-034 (L...
2023-03-20 15:20
1995
Izokibep Phase 2b/3 Hidradenitis Suppurative Data Presented at the 2023 American Academy of Dermatology Annual Meeting
* At 12 weeks, participants achieved high orders of HiSCR responses (HiSCR75 and above), including 33% achieving HiSCR100. * Safety results were consistent with previous trials of izokibep and the IL-17Ai class, with no increased risk of infection, including candida. SAN DIEGO ,SHANGHAI and SY...
2023-03-20 08:41
2544
AMGEN AND NSG BIOLABS ANNOUNCE ALBATROZ THERAPEUTICS AS WINNER OF FIRST AMGEN GOLDEN TICKET IN SINGAPORE
The Golden Ticket will help to boost the biotech startup's capabilities and to develop further the emerging biotech ecosystem inSoutheast Asia SINGAPORE, March 20, 2023 /PRNewswire/ -- Leading global biotechnology company Amgen and NSG BioLabs,Singapore's largest and leading provider of biotechn...
2023-03-20 08:00
2378
Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration
CHENGDU, China, March 17, 2023 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) announced its 2022 annual results. Focused on unmet clinical needs, the Company continued to efficiently develop innovative and differentiated pipelines, proactively carry out global strategic collaboration and a...
2023-03-18 08:00
5548
Hanmi Pharmaceutical's Combination Drug for Dyslipidemia Treatment, 'Rosuzet': Confirmed Non-inferiority Efficacy and Safety Compared to Monotherapy in 'The Lancet' & 'European Heart Journal'
SEOUL, South Korea, March 17, 2023 /PRNewswire/ -- Hanmi Pharmaceuticals (128940.KS), a subsidiary of Hanmi Science (008930.KS) in Korea, announced that the results of large-scale clinical trial with Rosuzet have been published in 'The Lancet' and the 'European Heart Journal'. R&D-oriented pha...
2023-03-17 21:00
3662
Samsung Biologics announces construction of Plant 5 to commence Bio Campus II capacity expansion
* The company plans to begin construction in the first half of 2023 and commence operations in 2025 * As part of Samsung Biologics' second Bio Campus, Plant 5 will hold a manufacturing capacity of 180,000 liters, expanding the company's total site capacity to 784,000 liters upon its completio...
2023-03-17 19:25
3068
SYMBYX announces promising Sydney Adventist Hospital clinical trial results for Parkinson's using the SYMBYX Neuro - a new light therapy wellness helmet
SYDNEY, March 17, 2023 /PRNewswire/ -- SYMBYX, an Australian medtech company developing light therapies for intractable disease conditions, today announced the results of a Sydney Adventist Hospital (commonly known as the San) triple-blinded, randomised controlled trial investigating the effects ...
2023-03-17 18:30
2101
GCCL Develops PBMC Resource Management System
To enhance accuracy and credibility of sample management and provide real-time information for customers YONGIN, South Korea, March 16, 2023 /PRNewswire/ -- GCCL (Global Clinical Central Lab), a company specializes in clinical trial sample analysis, announced onMar. 17 that it has built a resour...
2023-03-17 09:26
1637
YS BIOPHARMA TO RING THE OPENING BELL AND DEBUT ON NASDAQ
YS Biopharma Ordinary Shares and Warrants to Trade on the Nasdaq Under Tickers "YS" and "YSBPW" NEW YORK, March 17, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (the "Company" or "YS Biopharma"), a global biopharmaceutical company focusing on new generations of vaccines and therapeutic biologic...
2023-03-17 04:30
2488
Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration according to Interim Findings from a Phase 2a Study in OA Patients
SEOUL, South Korea, March 16, 2023 /PRNewswire/ -- OliPass Corporation, an RNA therapeutics platform company, disclosed that OLP-1002, a selective inhibitor of Nav1.7 sodium ion channel, showed strong analgesic efficacy and long therapeutic duration according to interim findings from a placebo-co...
2023-03-16 21:00
1863
Angel Yeast Showcases Latest Product Innovations at Food Ingredients China 2023
SHANGHAI, March 16, 2023 /PRNewswire/ -- Angel Yeast
2023-03-16 20:16
3917
Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003
SUZHOU, China, March 16, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed with 2.1mg/kg in a Phase I clinical study (JSKN003-102) of JSKN003, an Anti-HER2 bispecific ADC. ADC drugs have the advantages of highly specific targeting of anti...
2023-03-16 09:58
2414
Week's Top Stories
Most Reposted
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 296 media titles]
2024-11-28 17:24Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 280 media titles]
2024-11-25 10:00
Announcement of "Cyber Sousa Award" Winners of the 16th Xiamen International Animation Festival
[Picked up by 272 media titles]
2024-11-26 16:48
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
12916
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
9000
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
8155
